positive: the sourced evidence makes a specific case that the business is improving or under-appreciated. medium conviction: a reasonable case, resting on fewer or partly second-hand sources.
- the case, in short
In Q2 FY2027, revenue was INR 18,336 million, up 23% year-on-year, and profit after tax grew 58% year-on-year to INR 2,908 million.
“During Q2 FY2027, we delivered revenue of INR 18,336 million, representing a growth of 23% year-on-year, while EBITDA increased by 53% year-on-year to INR 4,804 million.”Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
“profit after tax grew 58% year-on-year to INR 2,908 million”Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- the main risk
A US FDA inspection of the Dundigal facility in October ended with four procedural observations.
“Our Dundigal facility also underwent a US FDA inspection during October and concluded with four procedural observations.”Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
in plain words
In Q2 FY2027, sales from its business were INR 18,336 million, up 23% compared with the same period a year earlier, and net profit, after all costs and tax, grew 58% to INR 2,908 million. Reported operating profit for the quarter was INR 4,804 million, so operating profit was 26% of revenue, compared with approximately 21% in the same quarter of the previous year. The US was the company's largest market, with revenues up 42% compared with the same period a year earlier to INR 11,795 million. A US FDA inspection of the Dundigal facility in October ended with four procedural observations.
why it may work
In Q2 FY2027, revenue was INR 18,336 million, up 23% year-on-year, and profit after tax grew 58% year-on-year to INR 2,908 million.
“During Q2 FY2027, we delivered revenue of INR 18,336 million, representing a growth of 23% year-on-year, while EBITDA increased by 53% year-on-year to INR 4,804 million.”Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
“profit after tax grew 58% year-on-year to INR 2,908 million”Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
During the quarter, CDMO revenues grew 31% year-on-year to INR 8,227 million, contributing approximately 45% of total revenues.
“During the quarter, CDMO revenues grew 31% year-on-year to INR 8,227 million, contributing approximately 45% of total revenues.”Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Reported EBITDA for the quarter was INR 4,804 million, an EBITDA margin of 26%, compared with approximately 21% in the same quarter of the previous year.
“Reported EBITDA for the quarter stood at INR 4,804 million, representing EBITDA margin of 26%, compared to approximately 21% in the corresponding quarter of the previous year.”Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
The US was the company's largest market, with revenues up 42% year-on-year to INR 11,795 million, and the company launched four products in the US market during the quarter.
“the US remained our largest market and delivered an outstanding performance during the quarter. Revenues grew 42% year-on-year to INR 11,795 million.”Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
“During the quarter, we launched four products in the US market”Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
what could go wrong
A US FDA inspection of the Dundigal facility in October ended with four procedural observations.
“Our Dundigal facility also underwent a US FDA inspection during October and concluded with four procedural observations.”Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Rest-of-world revenues were INR 2,044 million in the quarter and were affected by supply and tender issues in some markets, especially the delayed announcement of NUPCO tender results in Saudi Arabia.
“Revenues from rest of the world markets stood at INR 2,044 million during the quarter. Performance was impacted by certain market-specific supply and tender-related dynamics, especially delay of announcement of NUPCO tender results from Saudi Arabia.”Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
price and valuation facts
- Closed at its 52-week closing high.
- Last close ₹3,395 sits 100% of the way from the 52-week closing low (₹1,597.25) to the high (₹3,395).
- Its largest fall from a peak in the last year was 15.8% (maximum drawdown).
- P/E of 36.91x (standalone) is 44% below the median of its BSE 500 industry peers (sector peers when the industry has fewer than four).
- Annualised volatility over 3 months is 29.1%, lower than 61% of the BSE 500 scrips Dalal tracks.
- Median daily BSE traded value: ₹11.18 crore over 60 days.
dalal's own computed data (from exchange prices and bse fundamentals), not from the documents above. as of 16 nov 2026.
what is coming up
Additional bag manufacturing capacity installed during the year is awaiting a US FDA inspection, after which the company could sell products made on this line.
“Additional bag manufacturing capacity installed during the year is awaiting US FDA inspection, post which we could commercialize products from this line”Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
The company has initiated a greenfield project at Vizag SEZ, acquired land for it, and said it will seek Board approval for additional capex for this expansion in the coming quarter.
“We have also initiated a greenfield project at Vizag SEZ”Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
“We have acquired land for this purpose and working on the project plan. We will seek approval from the Board for the additional capex towards this expansion in the coming quarter.”Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
what would change the view
the view rests on these. if they stop being true, so does the view.
According to a whalesbook report, the company is keeping its guidance of 15% constant currency revenue growth for FY27.
“the company maintains a 15% constant currency revenue growth guidance for FY27”Gland Pharma Q2 Results Miss Estimates; Board Approves Rs 1,000 Cr Capex
the numbers
computed by dalal when the note was written.
price
- last close
- ₹3,395.00
- 1-day change
- 1.81%
- 52-week high (closing basis)
- ₹3,395.00
- 52-week low (closing basis)
- ₹1,597.25
- 52-week high (BSE, adjusted)
- ₹3,428.00
- 52-week low (BSE, adjusted)
- ₹1,575.00
as of 16 nov 2026
returns
- 1-week return
- 2.84%
- 1-month return
- 11.56%
- 3-month return
- 16.73%
- 6-month return
- 57.23%
- 12-month return
- 85.43%
- 3-month return relative to SENSEX
- 10.51%
- 6-month return relative to SENSEX
- 44.23%
- 12-month return relative to SENSEX
- 90.98%
as of 16 nov 2026
risk
- annualised volatility (3 months)
- 29.10%
- maximum drawdown (1 year)
- −15.82%
- distance from 52-week closing high
- 0.00%
- 5-day vs 60-day BSE volume
- 0.16×
as of 16 nov 2026
valuation
- P/E (standalone)
- 36.91×
- P/E (consolidated)
- 45.33×
- P/B
- 6.11×
- EPS (standalone)
- ₹91.97
- EPS (consolidated)
- ₹74.90
- P/E relative to industry median
- 0.56×
as of 16 nov 2026
quality
- return on equity
- 16.54%
- operating margin
- 44.16%
- net margin
- 30.31%
as of 16 nov 2026
size & liquidity
- median daily BSE traded value (60 days)
- ₹11 cr
- market capitalisation
- ₹56,021 cr
as of 16 nov 2026
latest results (standalone)
- revenue, standalone (Sep-26)
- ₹1,402 cr
- net profit, standalone (Sep-26)
- ₹425 cr
- EPS, standalone (Sep-26)
- ₹25.75
- operating margin, standalone (Sep-26)
- 44.16%
- revenue, standalone (Jun-26)
- ₹1,287 cr
- net profit, standalone (Jun-26)
- ₹364 cr
- EPS, standalone (Jun-26)
- ₹22.11
- operating margin, standalone (Jun-26)
- 41.37%
- revenue change Jun-26 → Sep-26
- 8.96%
- net profit change Jun-26 → Sep-26
- 16.60%
as of 14 nov 2026
dalal scores
- daily score
- 60/100
- monthly score
- 97/100
- six-month score
- 100/100
- long-term score
- 94/100
as of 16 nov 2026
not available: next results board meeting; days since last results filing.
P/E: the share price divided by the profit per share over the last year · market cap: the total value of all of a company’s shares at the current share price · Sensex: the main index of BSE, tracking the share prices of a fixed group of large companies. fundamentals from bse are standalone figures. scores are percentile ranks across the bse 500 (90 = better than 90% of them on that horizon’s recipe). 9 statements passed dalal’s source checks. 2 did not and are not shown.
pick history
every time it was listed, and how it went.
never on a list so far.
in the knowledge base
the latest filings and news.
- Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPSfilingbse· 16 nov 2026(opens the source in a new tab)
- Gland Pharma Ltd: Grant Of Options To Purchase Securitiesfilingbse· 16 nov 2026(opens the source in a new tab)
- Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Earnings Call Transcriptfilingbse· 12 nov 2026(opens the source in a new tab)
- Gland Pharma Ltd: Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015filingbse· 12 nov 2026(opens the source in a new tab)
- Gland Pharma reports 23% revenue growth in Q2 FY27 to INR 18,336 millionnewsinvestywise· 12 nov 2026(opens the source in a new tab)
- Gland Pharma Q2FY27 Results: Net profit up 58% YoY; guides 15% growthnewsscanx· 12 nov 2026(opens the source in a new tab)
- Gland Pharma shares rally 8% to hit 4-year-high post strong Q2; what brokerages say, check target pricesnewsmoneycontrol· 9 nov 2026(opens the source in a new tab)
- Gland Pharma Ltd: Announcement under Regulation 30 (LODR)-Change in Managementfilingbse· 9 nov 2026(opens the source in a new tab)
- Gland Pharma Q2 Results Miss Estimates; Board Approves Rs 1,000 Cr Capexnewswhalesbook· 9 nov 2026(opens the source in a new tab)
- Gland Pharma shares jump 7% to 52-week high; Nomura sees re-rating but Citi says 'sell'newscnbc-tv18· 9 nov 2026(opens the source in a new tab)
research ideas and things to consider, not personalised investment advice. every statement links to the filing or article it came from; numbers are computed by dalal from exchange data with their dates. ideas can and do lose money: the track record shows every pick, losers included. decide based on your own situation.